Sensitivity of cultured human pancreatic carcinoma cells to dihydroxyanthracenedione

George Fountzilas, Howard Gratzner, Lori O. Lim, Adel A. Yunis

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We tested the effectiveness of dihydroxyanthracenedione (DHAD) on cell growth of two human pancreatic carcinoma cell lines MlA PaCa‐2 and PANC‐1. At the level of ID50, the drug was almost equally effective against both cell lines. When the time exposure of MIA PaCa‐2 cells to the drug was increased from 1 h to continuous exposure for 5 days, the ID50 was decreased about three‐fold only (1.4 × 10−8 M and 4 × 10−9 M respectively). At the level of ID50 also the difference between 6 h exposure and continuous exposure for 5 days was minimal. In equimolar concentrations and with 1 h exposure, DHAD was more effective against MIA PaCa‐2 cells than other chemotherapeutic agents including adriamycin, mitomycin‐C, 5‐FU, vincristine, vindesine, vinblastine, VP‐16–213, bleomycin, cis‐platinum, asparaginase and acivicin. In concentrations of 5 × 10−7 M, DHAD caused about 40% inhibition of 14C‐thymidine incorporation of MIA PaCa‐2 cells. Treatment of MIA PaCa‐2 cells with the ID50 of DHAD for 1 h caused retardation of cellular traverse, with the major effect appearing to be in G2+M phase of the cycle. From these data DHAD appears to be a potent drug against human pancreatic carcinoma in vitro.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalInternational Journal of Cancer
Volume33
Issue number3
DOIs
StatePublished - Mar 15 1984

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Sensitivity of cultured human pancreatic carcinoma cells to dihydroxyanthracenedione'. Together they form a unique fingerprint.

  • Cite this